🔴 Ideaya Biosciences is trading 18.53% down in after-hours trading with no clear company-specific catalyst identified

Ideaya Biosciences is trading at $32.35, down 18.53%, with no clear company-specific catalyst identified for the after-hours decline on September 22, 2026.

• Recent coverage highlighted positive clinical progress, including first-patient dosing in the OptimUM-11 Phase 3 trial, rather than negative news.
• Broader markets were mixed; the Nasdaq Composite was up 0.62%, which does not explain the sharp drop.
• The move may reflect delayed or undisclosed information; monitoring is warranted.